A Controlled Trial of Erenumab in Migraine Prevention

Migraine prevention is an area of a large unmet medical need, with existing therapies often having modest efficacy and poor tolerability. Calcitonin gene‐related peptide (CGRP) receptor antagonism is a novel approach to migraine preventive therapy. Erenumab is a human monoclonal antibody against canonical CGRP receptor. The present study is a phase 3 trial intended to assess the efficacy and safety of erenumab for prevention of migraine in Japanese adults with episodic migraine (EM) and chronic migraine (CM). The study consists of a screening period (up to 7 weeks, including a 4‐week baseline period), a 24‐week double‐blind treatment period (DBTP), a 28‐week open‐label treatment period (OLTP), and an 8‐week safety follow‐up period (12 weeks after the last dose of investigational product).